Tilray Brands Inc. said Friday its first-quarter loss narrowed to $65.8 million, or 13 cents a share, from a loss of $34.6 million, or 9 cents a share, in the year-ago quarter. Revenue at the cannabis company fell 9% to $153.2 million. Analysts expected Tilray to lose 7 cents a share on revenue of $155.9 million, according to FactSet data. Shares of Tilray rose 3% in premarket trades Friday, adding to gains from the previous session on comments from President Joe Biden to pardon people for canna Read More...
Motley Fool
Why Agenus Stock Rose 18.4% on Thursday
Shares of Agenus (NASDAQ: AGEN), a clinical-stage biopharmaceutical company that specializes in immuno-oncology, saw its shares jump 18.4% on Thursday. First, the company on Wednesday said it planned to present data on botensilimab, a therapy that is being studied for its effectiveness as a combination drug or a monotherapy to active T-cell immune responses in patients who have pancreatic cancer, colorectal cancer, or melanoma, a type of skin cancer. Another move that helped push up the stock was the announcement of inside buying of Agenus stock by some members of the company’s board of directors on Wednesday, including Susan Hirsch, Wadih Jordan, Ulf Wiinberg, and Timothy Wright, totaling more than 30,000 Agenus shares.
